Mark Weiser
YOU?
Author Swipe
View article: Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial Open
LAI antipsychotics significantly delayed treatment discontinuation compared with oral antipsychotics in participants with early phase schizophrenia and comorbid SUD but not in those without SUD. While these findings provide robust evidence…
View article: Prebiotic soda lowers postprandial glucose compared to traditional soda pop: a randomized controlled trial
Prebiotic soda lowers postprandial glucose compared to traditional soda pop: a randomized controlled trial Open
Inadequate dietary fiber intake and excess added sugar intake are dietary factors attributed to the rise in obesity, type 2 diabetes, and associated cardiometabolic diseases. Until recently, consumers had limited options for finding simila…
View article: Differential associations between cytokine and complement proteins in the clinical high risk and first episode stages of psychosis: Blood based investigation across three international studies of psychosis: NEURAPRO, STEP and OPTiMiSE
Differential associations between cytokine and complement proteins in the clinical high risk and first episode stages of psychosis: Blood based investigation across three international studies of psychosis: NEURAPRO, STEP and OPTiMiSE Open
Dysregulation of inflammatory mediators and complement cascade proteins has been implicated in psychosis. In the current study, we aimed to investigate the relationship between complement cascade proteins and inflammatory cytokines in bloo…
View article: Neural activation changes following attention bias modification treatment or a selective serotonin reuptake inhibitor for social anxiety disorder
Neural activation changes following attention bias modification treatment or a selective serotonin reuptake inhibitor for social anxiety disorder Open
Background Delineation of changes in neural function associated with novel and established treatments for social anxiety disorder (SAD) can advance treatment development. We examined such changes following selective serotonin reuptake inhi…
View article: A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort Open
This study provides valuable insight into the early course of a broad range of clinical and functional aspects of illness in FES patients in routine clinical practice.
View article: Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial
Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial Open
Some but not other studies on oxytocin for schizophrenia, particularly those using a higher dose, indicate that oxytocin improves negative symptoms of schizophrenia. We performed an add-on randomized controlled trial to examine the effect …
View article: Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies Open
There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many differ…
View article: Technologically assisted intensive home treatment: feasibility study
Technologically assisted intensive home treatment: feasibility study Open
Introduction In recent year, many attempts have been made to provide patients with alternatives to psychiatric hospitalization during acute distress. Although several hospitalization alternatives have been offered, most of them still requi…
View article: A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder
A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder Open
This large randomized controlled trial examined the effect of naproxen, simvastatin or both on patients with schizophrenia. This was a large multi-center, twelve-week, randomized, double-blind, placebo-controlled, four-arm clinical trial a…
View article: Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study Open
Background and Hypothesis This analysis examined the relationship between cannabis use, compliance with antipsychotics and risk for relapse in patients in remission following a first episode of schizophrenia, schizophreniform, or schizoaff…
View article: Long-term effects of Roluperidone on negative symptoms of schizophrenia
Long-term effects of Roluperidone on negative symptoms of schizophrenia Open
Roluperidone has antagonist properties for 5-HT2A, sigma2, α1A- and α1B-adrenergic receptors, but no dopaminergic binding affinities. In 2 randomized controlled trials (RCT), treatment improved negative symptoms of schizophrenia and social…
View article: Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial Open
Background and Hypothesis Treatment response to specific antipsychotic medications is difficult to predict on clinical grounds alone. The current study hypothesizes that the baseline complement pathway activity predicts the treatment respo…
View article: Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder
Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder Open
Trial Registration: ClinicalTrials.gov identifier NCT01320982.
View article: Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Open
Background This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial fo…
View article: Predicting individual variability in task‐evoked brain activity in schizophrenia
Predicting individual variability in task‐evoked brain activity in schizophrenia Open
What goes wrong in a schizophrenia patient's brain that makes it so different from a healthy brain? In this study, we tested the hypothesis that the abnormal brain activity in schizophrenia is tightly related to alterations in brain connec…
View article: The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial
The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial Open
Nicotinic agonists have been shown to improve cognition and mood, but this improvement is inconsistent and short-lived, possibly due to receptor desensitization. Positive Allosteric Modulators (PAMs) of the nicotinic alpha-7 nicotinic-acet…
View article: Misreporting of Results of Research in Psychiatry
Misreporting of Results of Research in Psychiatry Open
Few studies address publication and outcome reporting biases of randomized controlled trials (RCTs) in psychiatry. The objective of this study was to determine publication and outcome reporting bias in RCTs funded by the Stanley Medical Re…
View article: Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials Open
Two previous randomized controlled trials (RCTs) suggested that adjunctive aspirin is efficacious in treating schizophrenia. We conducted two 16-week double-blind randomized placebo-controlled RCTs of adjunctive 1000 mg aspirin vs placebo …
View article: Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism
Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism Open
The clinical and etiological relation between autism spectrum disorders (ASD) and schizophrenia is unclear. The degree to which these disorders share a basis in etiology has important implications for clinicians, researchers, and those aff…
View article: Comprehensive Gene Expression Analysis Detects Global Reduction of Proteasome Subunits in Schizophrenia
Comprehensive Gene Expression Analysis Detects Global Reduction of Proteasome Subunits in Schizophrenia Open
Background The main challenge in the study of schizophrenia is its high heterogeneity. While it is generally accepted that there exist several biological mechanisms that may define distinct schizophrenia subtypes, they have not been identi…